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Abstract
Increasing evidence suggests a contribution of epigenetic processes in promoting cancer and autoimmunity.
Myasthenia gravis (MG) is an autoimmune disease mediated, in approximately 80% of the patients, by antibodies
against the nicotinic acetylcholine receptor (AChR+). Moreover, epithelial tumours (thymomas) are present in about
10-20% of the patients, and there is indication that changes in DNA methylation might contribute to the risk and
progression of thymomas. However, the role of epigenetics in MG is still not completely clarified. In the present study
we investigated if a common polymorphism (-579G>T: rs1569686) in the promoter of the DNMT3B gene coding for
the DNA methyltransferase 3B, an enzyme that mediates DNA methylation, increases the risk to develop MG or MG-
associated thymomas. The study polymorphism was selected based on recent reports and a literature meta-analysis
suggesting association with increased risk of various types of cancer. We screened 324 AChR+ MG patients (140
males and 184 females, mean age 56.0 ± 16.5 years) and 735 healthy matched controls (294 males and 441
females, mean age 57.3 ± 15.6 years). 94 of the total MG patients had a thymoma. While there was no association
with the whole cohort of MG patients, we found a statistically significant association of the DNMT3B -579T allele (OR
= 1.51; 95% CI=1.1-2.1, P = 0.01) and the TT homozygous genotype (OR = 2.59; 95% CI=1.4-4.9, P = 0.006) with
the risk of thymoma. No association was observed in MG patients without thymoma, even after stratification into
clinical subtypes. Present results suggest that the DNMT3B -579T allele might contribute to the risk of developing
thymoma in MG patients, particularly in homozygous TT subjects.
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Introduction
Increasing evidence suggests a contribution of epigenetic
modifications in complex diseases such as cancer and
autoimmune disorders [1-3]. The term epigenetics refers to
heritable and reversible modifications that alter gene
expression without resulting in direct changes of the primary
DNA sequence. Several epigenetic mechanisms are known,
including DNA methylation, covalent modifications of histone
tails, and nucleosome positioning, all interacting to determine
chromatin folding and the relative accessibility of a given
genetic locus to activating and suppressing transcription factors
[4], and non coding RNAs affecting gene expression levels [5].
DNA methylation represents one of the most studied
epigenetic marks for gene regulation; it consists of the addition
of a methyl group to the 5’ position of the cytosine pyrimidine
ring (5-methylcytosine) mediated by DNA methyltransferase
enzymes (DNMTs) using S-adenosylmethionine (SAM) as the
methyl donor compound [6]. Methylation of CpG rich regions
(CpG islands) in the promoter of a given gene is commonly
associated with gene silencing [6]. Most of the studies
performed so far in autoimmune diseases have focused on
DNA methylation impairments in systemic lupus erythematosus
and rheumatoid arthritis [3]. There is however increasing
evidence of methylation changes and/or impaired DNMTs
activity in other autoimmune disorders such as Sjögren’s
syndrome, multiple sclerosis, systemic sclerosis, psoriasis, and
autoimmune thyroid diseases [3,7,8].
Myasthenia Gravis (MG) is a prototypic antibody-mediated
autoimmune disease. In approximately 80% of the patients the
disease is mediated by auto-antibodies against the nicotinic
acetylcholine receptor (AChR) [9]. Despite emerging evidence
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of epigenetic changes in promoting autoimmunity, the role of
epigenetics in MG is still scarcely investigated [10]. Moreover,
MG is often associated with pathological changes of the
thymus: thymic epithelial tumours are present in about 10-20%
of MG patients, while up to 80% of the patients with early onset
of disease have thymic hyperplasia [11]. Thymoma is an
uncommon neoplasm derived from thymus epithelial cells, and
studies aimed at analyzing DNA methylation of tumour-related
genes showed altered methylation patterns of many of them,
including among others MGMT, hMLH1, p16/INK4, and
RASSF1A, whose increased methylation significantly
correlated with tumour severity [12,13].
The goal of the present study was to investigate if a common
polymorphism (-579G>T: rs1569686) in the promoter of the
DNMT3B gene coding for the DNA methyltransferase 3B, one
of the key de novo enzymes mediating DNA methylation,
increases the risk to develop MG or MG-associated thymomas.
The selected polymorphism has been suggested to impair DNA
methylation of tumor suppressor genes, therefore impairing
their expression levels, and for this reason it was investigated
as a susceptibility factor for several cancer types [16-21]. A
meta-analysis of published studies revealed that the mutant
allele (T) is associated with increased risk of cancer compared
to the wild type one (G) [22]. Moreover, DNMT3B promoter
polymorphisms have been associated with global DNA
methylation and are increasingly investigated in other complex
diseases than cancer [23-27]. Indeed, clinical studies showed
association with wide-spread DNA methylation and suicide
attempts in psychiatric patients [23], with increased risk of
early-onset schizophrenia [24], with risk of giving birth to a child
with Down syndrome [25], as well as with increased risk of the
autoimmune disease oral lichen planus [26], and with the
progression of joint destruction in rheumatoid arthritis [27].
Materials and Methods
Study population
A total of 324 AChR+ MG patients and 735 healthy matched
unrelated controls were recruited at the Myasthenia Clinic
(Department of Neuroscience and Cardiac and Thoracic
Department) of the Pisa University Hospital, at the Institute of
General Pathology of the Catholic University of Rome, and at
the Department of Translational Research and New
Technologies in Medicine and Surgery of the University of Pisa.
Disease diagnosis was based on characteristic signs and
symptoms of MG coupled with an anti-AChR antibody positive
test; patients with an anti-AChR antibody negative test were
excluded from the present study. The main clinical
characteristics of MG patients are listed in Table 1. The mean
age (±S.D.) of the patients was 56.0 (± 16.5) years. According
to disease onset age, patients were divided into early onset
(≤45 years) and late onset (>45 years). According to the
Osserman classification, they could be divided into pure ocular
(class I) and generalized MG (class IIA, IIB, III, IV). MG was
associated with different autoimmune disorders (AID) in 51
(15.7 %) out of 324 patients (see Table 1 for details). All
patients had computed tomography (CT) scans of the chest
and thymectomy was performed in 179 out of 324 patients
according to the CT scan findings. Overall 94 patients (29.0%)
had a thymoma. Thymic hyperplasia was found in 95 cases
(29.3%), and a normal (involuted) thymus in 135 cases
(41.7%). The control group includes 735 healthy volunteer
subjects with no history of cancer or autoimmune diseases
matched for age and gender with the patients (Table 1). All
individuals were white Caucasians of Italian descent as
determined by grandparents origin; each subject gave an
informed written consent for genotype analysis before blood
drawing. The study was performed in accordance to the
Declaration of Helsinki, and was approved by the Ethics
Committees of the Pisa University Hospital and of the Catholic
University of Rome.
Genotyping procedures
Genomic DNA was extracted from peripheral blood
lymphocytes by means of the QIAamp® Blood Mini Kit
(Quiagen, Milan, Italy) according to the manufacturer’s
protocol. Genotyping analysis was performed by means of
PCR-RFLP techniques following the protocol of Lee et al. [28]
with minor modifications [29]. Briefly, a 225 bp product was
amplified using 1.25 Units of Taq DNA polymerase (Invitrogen,
Milan, Italy), 10 pmol of each primer (forward: 5’-GAG GTC
TCA TTA TGC CTA GG-3’ and reverse: 5’-GGG AGC TCA
CCT TCT AGA AA-3’), 0.15mM of each dNTPs, 1.5mM MgCl2,
and 40 ng of genomic DNA in a total volume of 25µl. PCR
conditions were 35 cycles of 30s at 95°C, 45s at 56°C, and 45s
at 72°C, preceded by an initial denaturation step of 5 min at
95°C and followed by a final elongation step of 10 min at 72°C.
Table 1. Demographic characteristics of Myasthenia Gravis
patients and Controls.
Characteristics
MG patients, Total No.
= 324
Controls, Total
No. = 735
Gendera: Females (%) / Males (%) 184 (56.8) / 140 (43.2) 441 (60.0) / 294(40.0)
Ageb (years): Mean ± S.D. 56.0 ± 16.5 57.3 ± 15.6
Age at onset (years): ≤ 45 (%) / > 45
(%) 170 (52.5) / 154 (47.5)  
Antibodies anti-AchR+ 324 (100%)  
Osserman classification: Grade I 56 (17.3%)  
Osserman classification: Grade IIA 78 (24.1%)  
Osserman classification: Grade IIB 182 (56.2%)  
Osserman classification: Grade III 3 (0.9%)  
Osserman classification: Grade IV 5 (1.5%)  
Associated autoimmune diseases
(AID)c 51 (15.8%)  
Thymic histology: normal thymus 135 (41.7%)  
Thymic histology: thymoma 94 (29.0 %)  
Thymic histology: hyperplasia 95 (29.3 %)  
a. Gender: no significant difference between MG patients and controls
b. Age: no significant difference between MG patients and controls
c. Associated autoimmune diseases (AID): Hashimoto’s thyroiditis: 16 cases;
Graves-Basedow disease: 14 cases; Type 1 Diabetes: 7 cases; Others: 14 cases.
doi: 10.1371/journal.pone.0080846.t001
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Overnight digestion at 37°C with Pvu II (Fermentas, Milan,
Italy) resulted in an undigested 225-bp product for the wild type
allele (G), and in 132- and 93-bp products for the mutant allele
(T). Digestion products were visualized after electrophoresis on
a 2% agarose gel containing ethidium bromide. Samples with
previously confirmed wild-type, heterozygous and mutant
genotypes [29] have been used as internal quality controls
during PCR-RFLP reactions.
Statistical analyses
Differences in mean age and gender between groups were
evaluated by means of the Student’s T-test, and Fisher’s exact
test, respectively. To verify that genotype frequencies were in
Hardy-Weinberg equilibrium in controls we used Chi-square
(χ2) analysis. Differences in allele and genotype distributions
between groups have been evaluated by means of Fisher’s
exact test. Odds ratios (ORs) have been calculated by means
of unconditional logistic regression and given with 95%
confidence intervals (CIs). All individual values were analyzed
with the SPSS 16.0 statistical package for Windows. The
statistical power of the study was evaluated by means of the
statistical package QUANTO 1.2.4.exe. Given a case-control
cohort of at least 300 cases and 700 controls, and a minor
allele frequency (MAF) of 31% in Controls, the study had an a
priory power of 82% to detect differences in allele frequencies.
Results
Allele and genotype frequencies generated by the DNMT3B
-579G>T polymorphism in patients and controls are shown in
Tables 2 and 3, respectively . Genotype distributions in controls
conformed to Hardy-Weinberg equilibrium (P = 0.18). No
difference in allele and genotype frequencies was observed
between patients and controls when MG patients were
considered as a whole (Tables 2 and 3). After stratification of
MG patients into three subgroups according to thymic
pathology (normal thymus, thymic hyperplasia and thymoma),
the comparison of each of the three subgroups with controls
revealed a significant association of the DNMT3B -579T allele
with increased thymoma risk (OR = 1.5; 95% CI = 1.1-2.1, P =
0.01). Moreover, the homozygous TT genotype was associated
with an increased thymoma risk compared to the homozygous
GG one (OR = 2.59; 95% CI = 1.4-4.9, P = 0.0059). Both
associations remained significant even after Bonferroni’s
correction for multiple comparisons (Tables 2 and 3). Given the
number of thymoma cases (94) and controls (735), a post-hoc
power analysis revealed that the study had >90% power to
detect differences in allele frequencies. No difference in allele
or genotype distributions was observed between MG patients
with thymic hyperplasia and controls, or between MG patients
with normal thymus and controls.
We also compared allele and genotype frequencies
generated by the DNMT3B -579G>T polymorphism in MG
patients stratified according to disease age at onset (≤45 years
vs. > 45 years), to disease severity (less severe forms: Grade I
+ IIA vs. more severe forms: Grade IIB + III + IV), or to the
presence/absence of associated autoimmune diseases
(associated AID vs. no associated AID). No difference in allele
and genotype frequencies was observed in young onset vs.
late onset MG patients, in less severe vs. more severe MG, or
in patients with associated AID with respect to those with no
associated AID (data not shown).
Discussion
In order to shed some light on the role of epigenetics in both
MG and MG-associated diseases, we analyzed the DNMT3B
-579G>T polymorphism in a large population of MG patients of
Italian descent. Overall, no association of the studied
polymorphism with MG was observed, even after stratification
of the patients according to different clinical parameters like
age at onset, disease severity according to Osserman
classification, or presence/absence of other autoimmune
diseases. However, when we stratified MG patients according
Table 2. DNMT3B -579G>T allele frequencies in
Myasthenia Gravis patients and Controls.
Alleles
Controls,
No. (%)
MG (Total),
No. (%)
MG
(Thymomas),
No. (%)
MG
(Hyperplasia),
No. (%)
MG
(Normal
Thymus),
No. (%)
Allele G 1007(68.5)
426
(65.7) 111 (59.0) 127 (66.8) 188 (69.6)
Allele T 463(31.5)
222
(34.3) 77 (41.0) 63 (33.2) 82 (30.4)
OR
(95%CI) T
vs G
-- 1.13 (.93-1.4) a
1.51 (1.1-2.1)
a 1.08 (.78-1.5) a
0.95(.
72-1.3) a
P-value -- 0.226 0.010b 0.679 0.775
a. Compared to the control group
b. Fisher’s exact test P-value = 0.01; Bonferroni’s corrected P-value = 0.04
doi: 10.1371/journal.pone.0080846.t002
Table 3. DNMT3B -579G>T genotype frequencies in
Myasthenia Gravis patients and Controls.
Genotypes
Controls,
No. (%)
MG (Total),
No. (%)
MG
(Thymomas),
No. (%)
MG
(Hyperplasia),
No. (%)
MG
(Normal
Thymus),
No. (%)
GG 337(45.8) 148 (45.7) 34 (36.2) 46 (48.4) 68 (50.4)
GT 333(45.3) 130 (40.1) 43 (45.7) 35 (36.8) 52 (38.5)
TT 65 (8.9) 46 (14.2) 17 (18.1) 14 (14.8) 15 (11.1)
OR: GT
vs. GG --
0.89 (.
67-1.2) a
1.28 (.80-2.1)
a 0.77 (.48-1.2) a
0.77 (.
52-1.1) a
OR : TT
vs. GG --
1.61
(1.1-2.5) a
2.59
(1.4-4.9)a,b 1.58 (.82-3.0) 
a 1.14 (.
62-2.1) a
a. OR and (95%CI) compared to the control group
b. Fisher exact Test P-value = 0.0059; Bonferroni’s corrected P-value = 0.04
doi: 10.1371/journal.pone.0080846.t003
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to thymus pathology, we found a statistically significant
association of the T allele with the presence of thymoma,
particularly among carriers of the homozygous TT genotype.
Present data are in agreement with a literature meta-analysis
suggesting an increased risk of cancer associated with the
presence of the DNMT3B -579T allele [22]. That meta-analysis
included ten studies performed in Asian populations, and one
single study performed in Caucasians. After stratification into
ethnic groups, the authors observed association with cancer
risk in Asians, likely because almost all the available studies
had been performed in that ethnic group [22]. Interestingly, the
frequency of the DNMT3B -579G allele in Asians is much lower
than that of the DNMT3B -579T one [22]. However, to the best
of our knowledge, previous studies have assessed the role of
this polymorphism in many different cancers, including those of
the gastro-intestinal and respiratory apparatuses, head and
neck carcinomas, and nasopharyngeal carcinomas [14-21], but
never in thymoma, either alone or associated to MG.
Hirose and coworkers [12] investigated DNA methylation in
26 thymomas and 6 thymic carcinomas to clarify the
association between aberrant DNA methylation and the clinico-
pathological features of thymic neoplasms. They observed that
almost 50% of thymic epithelial tumours showed aberrant
methylation, and that the frequency of tumour methylation was
correlated with their malignant behaviour. Moreover, also the
number of hypermethylated genes increased with increasing
malignant behaviour, suggesting that promoter
hypermethylation, and the consequent down-regulation of
specific tumour suppressor genes, may play an important role
in the development of aggressive and invasive thymic epithelial
tumours [12]. Their results were in accordance with Chen and
coworkers, who found that tumor suppressor genes and DNA
repair genes, including hMLH1, RASSF1A, MGMT, p16/INK4,
DAPK, FHIT, RAR2, CDH1, and APC, are frequently
hypermethylated in thymic epithelial tumours, all found to be
methylated in almost 20 to 40% of the cases [13,30]. Several
studies reported that DNMTs are upregulated in thoracic
neoplasms, and that those cancers are characterized by global
DNA hypomethylation and gene specific hypermethylation
(reviewed in 30), and an inverse correlation between DNMT3B
levels and global DNA methylation was observed in thymic
epithelial tumours [13].
The functional role of the DNMT3B -579G>T polymorphism
is not yet completely elucidated. Some authors suggest that it
can directly impair promoter activity and gene expression
levels, and others observed a linkage disequilibrium between
rs1569686 and other DNMT3B promoter polymorphisms,
namely −149C>T (rs2424913) and -283T>C (rs6058870),
which have been functionally associated with promoter activity
and gene expression levels [22,25,28,31]. Taken overall,
results from those studies coupled with the evidence of an
association of the DNMT3B -579G>T polymorphism with
various types of cancer, suggest that this polymorphism might
either have a functional role on gene expression levels, or be a
tag SNP of functional haplotypes [22,28,31]. In this regard,
several investigators observed a correlation between DNMT3B
promoter polymorphisms, DNMT3B protein levels, and DNA
methylation levels, suggesting that the increased risk of cancer
observed in carriers of those polymorphisms might be due to
impairments of DNA methylation in cancer cells [22,32].
Except the presence of thymoma, no other investigated MG
clinical characteristic was associated with this polymorphism in
our population. Interestingly, others evaluated the contribution
of this polymorphism to the onset and progression of
autoimmune thyroid disease, and found no association [33].
The observed lack of association of the study polymorphism
with MG risk or age at onset does not exclude that other
epigenetic biomarkers might be linked to the disease.
Unfortunately, little is still known concerning epigenetic
modifications in MG, as the few available studies are focused
on DNA methylation in thymoma specimens [30]. Therefore,
due to the absence of available genome-wide data, the role of
DNA methylation in MG is still to be clarified. By contrast,
several studies revealed global or gene specific
hypomethylation, impaired activities of enzymes such as
DNMTs or methyl CpG binding proteins, histone tail
modifications, and/or changes in non coding RNAs, in
autoimmune diseases such as systemic lupus erythematosus,
rheumatoid arthritis, Sjögren’s syndrome, psoriasis, multiple
sclerosis, and systemic sclerosis, among others [3,7,8],
suggesting that further studies are needed to elucidate the
possible contribution of epigenetics to the pathogenesis of MG.
Conclusions
The thymus plays distinct roles in the pathogenesis of the
different AChR+ MG subtypes. Inflammatory, neoplastic and
age-related alterations of the thymus are of pivotal relevance
for the initiation of anti AChR autoimmunity in early onset MG,
thymoma-associated MG and, likely, late onset MG,
respectively [34]. At best of our knowledge the present is the
first investigation of DNMT3B promoter polymorphisms in MG
patients. Our study suggests that the presence of the DNMT3B
-579T allele might represent a risk factor for the development
of MG-associated thymomas, particularly in carriers of the
homozygous TT genotype, while it probably does not have
effect on other MG subtypes. Therefore, the analysis of this
polymorphism could help to identify those AChR+ MG
individuals at increased risk to develop a thymoma.
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